Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company based in Salt Lake City, has entered into a securities purchase agreement with institutional investors to raise approximately $3 million through a private placement. The transaction, which is set to close on or about May 21, 2026, involves the sale of 1,647,447 shares of common stock and warrants to purchase an additional 3,294,894 shares. The effective offering price is established at $1.821 per share, with the warrants having an exercise price of $1.571 per share and a five-year expiration from the date of issuance. Maxim Group LLC is serving as the sole placement agent for this offering.

Co-Diagnostics specializes in the development, manufacture, and marketing of advanced molecular diagnostic technologies. The company’s proprietary platform is designed for the detection and analysis of nucleic acid molecules, such as DNA and RNA, which are critical in diagnosing various medical conditions. The funds raised from this private placement are expected to support the company’s ongoing research and development initiatives, particularly in enhancing its diagnostic technologies and expanding its market reach.

The molecular diagnostics sector has experienced significant growth, driven by increasing demand for rapid and accurate testing solutions, particularly in the wake of the COVID-19 pandemic. Companies in this space are focusing on innovation and the development of new tests that can address a broader range of health conditions. Co-Diagnostics' unique offerings, including its Co-Dx PCR platform, position it well within this competitive landscape, enabling it to capitalize on the growing need for advanced diagnostic tools.

The strategic rationale behind this fundraising effort lies in Co-Diagnostics' aim to bolster its financial position and accelerate its product development pipeline. By securing institutional investment, the company not only enhances its liquidity but also reinforces its credibility in the market. This move is indicative of a broader trend where molecular diagnostics firms are seeking to attract institutional capital to fund their growth strategies amid a rapidly evolving healthcare environment.

Looking forward, the successful completion of this private placement may have broader implications for the molecular diagnostics market. As companies like Co-Diagnostics continue to innovate and expand their product offerings, the sector is likely to witness increased competition and investment activity. The ability to attract institutional investors reflects confidence in the growth potential of molecular diagnostics, suggesting that the market will continue to evolve and adapt to meet the demands of healthcare providers and patients alike.